Tempus AI (TEM) Acquires Ambry Genetics in $600M Precision Medicine Push
We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at where Tempus AI, Inc.
The American Journal of Managed Care21h
Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...
Mutations in two gene pairs point to a promising drug target in 5% of adult cancers
Scientists from the Cancer Dependency Map (DepMap) at the Broad Institute of MIT and Harvard and Columbia University have ...
Myriad Genetics secures patents for cancer MRD tests
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...
Kaleido Scope14h
Leavenworth and Markert published in Nature Communications
For more information, refer to the full study in Nature Communications.